U.S. Markets close in 2 hrs 18 mins

GlaxoSmithKline plc (GSK)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
43.9201-0.15 (-0.34%)
As of 1:42PM EDT. Market open.
People also watch
AZNNVSSNYLLYBMY
Full screen
Previous Close44.0700
Open44.0400
Bid43.9700 x 1600
Ask43.9800 x 1000
Day's Range43.8900 - 44.0950
52 Week Range37.2000 - 45.5800
Volume1,129,519
Avg. Volume3,004,204
Market Cap106.68B
Beta1.06
PE Ratio (TTM)50.37
EPS (TTM)0.87
Earnings DateFeb 1, 2017 - Feb 6, 2017
Dividend & Yield1.95 (4.41%)
Ex-Dividend Date2017-05-10
1y Target Est47.55
Trade prices are not sourced from all markets
  • Forbes5 hours ago

    The Forgotten $35 Billion U.S. Healthcare Problem

    Each year, more than 23,000 people die in the U.S. as a result of bacterial infections that are resistant to antibiotics – the equivalent of a Boeing 747 crashing each week. Worse, there are at least 2 million people each year who acquire serious infections by bacteria resistant to antibiotics.

  • GSK's new CEO aims to divest sports nutrition brand: sources
    Reuters5 days ago

    GSK's new CEO aims to divest sports nutrition brand: sources

    GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday. GSK bought the business, which makes protein bars, drinks and powders, for 162 million pounds ($205 million) in 2010 under previous CEO Andrew Witty. The original acquisition was seen as complementing GSK's Lucozade sports drinks.

  • Glaxo's (GSK) Shingles Candidate Phase III Data Positive
    Zacks5 days ago

    Glaxo's (GSK) Shingles Candidate Phase III Data Positive

    GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.